SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crowd is excited about Crow With Knife ($CAW.X), a meme token, with community members highlighting its fully circulated supply, active community, and multichain functionality across $SOL.X, BSC, $CRO.X, and $ETH.X. There is also discussion around its deflationary burn mechanism and partnerships.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around the project's consistent grind and recent milestones, fueled by a strong belief in its potential within the meme coin space on the Solana network. The community is actively discussing the coin's path to number one trending and eagerly anticipating upcoming utility releases, solidifying their conviction in Brokecoin's long-term prospects. With a focus on community engagement and transparency, Brokecoin aims to differentiate itself in the crowded altcoin market.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as the community eagerly anticipates the mainnet launch and discusses its potential impact on the broader blockchain landscape. The excitement is fueled by its high transaction speed and institutional backing, with community members emphasizing partnerships and a Google Cloud endorsement. Some investors are drawing comparisons to Solana's past performance, envisioning substantial growth potential.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as the community discusses its potential inclusion in the S&P 500, with the official announcement expected soon; the addition could lead to increased visibility and investment, though some investors are wary of a potential "sell the news" event. Community members are also weighing in on the platform's user experience, active trader focus, and comparison to competitors, while others are still referencing the company's involvement in the 2020 GME situation. Upcoming catalysts such as the Robinhood summit next week and anticipated Fed rate cuts are adding to the speculative buzz.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors assess its potential amid the AI-driven automation landscape, with discussions focusing on its growth prospects and recent analyst ratings. Community members are debating whether the company is undervalued, citing its strong market position and partnerships, while others express concern over insider selling and the stock's historical performance. Speculation about a potential buyout is also circulating, adding to the heightened interest in PATH.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending as investors anticipate earnings, with community members discussing potential outcomes amid concerns about rising coffee prices and tariffs. Some are optimistic about the company's growth and expansion plans, while others express caution due to its high valuation and potential for volatility. Overall, the community is weighing the potential for BROS to continue disrupting the coffee market against macroeconomic headwinds.

XDC Network is an enterprise-ready hybrid Blockchain technology company optimized for international trade and finance. The XDC Network is powered by the native coin called XDC. The XDC protocol is architected to support smart contracts, 2000TPS, 2seconds transaction time, KYC to Masternodes (Validator Nodes). The XDC Chain (XinFin Digital Contract) uses XinFin Delegated Proof of Stake (XDPoS), with the intending to create a ‘highly-scalable, secure, permission, and commercial grade’ blockchain network. XinFin mainnet token XDC and also creates an opportunity to utilize the XinFin’s real-world use-cases such as TradeFinex.org, helps small and medium businesses or institutions originate their own financial requirements in a digital, fully structured manner so that they can distribute it to the bank or non-bank funders themselves using a common distribution standard.

XinFin Network

XinFin Network ($XDC.X) is trending as the community anticipates potential listings on major exchanges like Kraken and Binance, while also highlighting recent integrations and partnerships. Some users are speculating about the impact of real-world asset tokenization and its relationship with BlackRock. Others discuss price predictions, ISO compliance, and the coin's utility.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending amid discussions surrounding a proposed compensation package for Elon Musk, potentially worth $1 trillion, tied to ambitious long-term growth targets. The community is debating the feasibility and fairness of the package, with some questioning its impact on shareholders and the company's future, particularly regarding its focus on AI, robotics, and sustainable energy amid a changing EV landscape.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending as the community discusses potential pumps, relistings on major exchanges, and the possibility of reducing the circulating supply through burns and staking. Some users are linking LUNC's potential to broader market trends and even political figures, while others are skeptical about its long-term prospects. Community members are also promoting specific projects aimed at reviving the LUNC ecosystem.

Katapult Holdings, Inc. is an e-commerce focused financial technology company. The firm is engaged in the provision of e-commerce point-of-sale lease-purchase options for nonprime U.S. consumers. It offers its customers a lease purchase transaction processing system with no long-term obligation and options for ownership. The company was founded in August 2019 and is headquartered in Plano, TX.

Katapult Holdings Inc

KPLT is trending due to a potential turnaround and positive Q4 performance update, with gross originations growing double-digits year-over-year. Community members are discussing the low market cap relative to revenue and comparing it to other players in the BNPL space like SEZL, with some expressing optimism for a significant price increase. Some investors are also excited about the potential for a short squeeze, and a renewed credit facility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet

The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

Shares of uniQure N.V. (QURE) were in the spotlight on Friday morning after its first quarter (Q1) revenue fell 81% year-on-year (YoY) while losses narrowed.The gene therapy company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/09/3078125/0/en/uniQure-Announces-First-Quarter-2025-Financial-Results-and-Highlights-of-Recent-Company-Progress.html">reported</a> revenue for the three months ended March of $1.6 million, compared to $8.5 million in the same period of 2024, and below an analyst estimate of $6.71 million, as per Finchat data.The company attributed the revenue fall to a decrease of $4 million in contract manufacturing of HEMGENIX gene therapy for biotherapeutics company CSL Behring, among other factors.uniQure, however, narrowed its quarterly loss to $0.82 per share, compared to a loss of $1.36 in the corresponding period of 2024. Analysts were estimating a loss of $1.06 per share.The narrowing of the net loss in the quarter was driven by a significant reduction in the company’s operating expenses, as it slashed employee-related expenses, facility expenses, and costs related to preclinical supplies.The firm ended the quarter with cash, cash equivalents, and current investment securities of approximately $409 million, expected to fund its operations into the second half of 2027.The company is now seeking U.S. FDA approval for its AMT-130 gene therapy as a treatment for Huntington’s disease.CEO Matt Kapusta said that the company expects to provide a regulatory update on AMT-130 in the second quarter, including guidance on the potential timing for its application to the FDA seeking approval to distribute the therapy.On Stocktwits, retail sentiment around uniQure remained unmoved within the ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_8_08_00_AM_png_281dbf2952.webp" alt="QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE/sentiment">QURE stock</a> declined by 32% this year but is up by about 142% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-reports-positive-data-from-cancer-drug-trial/chiWpd3RblJ">AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode

The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 

Equity

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Shares of gene therapy developer uniQure N.V. (QURE) shot up 41% on Thursday afternoon after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.uniqure.com/investors-media/press-releases">announced</a> that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its AMT-130 gene therapy for the treatment of Huntington’s disease.The new designation is in addition to the existing Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations granted to AMT-130.uniQure CEO Walid Abi-Saab said that the designation underscores both the urgent need for effective treatments for Huntington’s disease and the encouraging interim data demonstrating that AMT-130 has the potential to slow disease progression.He added that the company looks to commercialize the drug as quickly as possible.Forty-five patients have received AMT-130 to date as part of trials, the company stated, while adding that an additional regulatory update regarding its Biologics License Application submission to the FDA requesting marketing approval is expected in the second quarter.Huntington’s disease is a rare, inherited neurodegenerative disorder. According to a 2021 study in Neuroepidemiology, approximately 70,000 people have been diagnosed with Huntington’s disease in the U.S. and Europe, with hundreds of thousands of others at risk of inheriting it.FDA’s Breakthrough Therapy designation is intended to expedite the development and review of investigational therapeutic candidates that are intended to treat a serious condition, and if preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy.On Stocktwits, retail sentiment around uniQure flipped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘low’ to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1292/302;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_12_38_37_PM_png_86c013b014.webp" alt="QURE's Sentiment Meter and Message Volume as of 12:40 p.m. ET on April 17, 2025 | Source: Stocktwits" width="1292" height="302"><figcaption>QURE's Sentiment Meter and Message Volume as of 12:40 p.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down approximately 27% year-to-date but up about 183% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/spirit-airlines-appoints-dave-davis-as-ceo/chQEDnoRbfA">Spirit Airlines Appoints Dave Davis As CEO After Emerging From Bankruptcy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic

The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130.

CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B CSL Behring's Gene...

Shares of gene therapy company uniQure more than doubled on Tuesday before trimming some gains, reaching their highest levels since mid-June 2023.The surge came after uniQure announced it had reached an agreement with the U.S. Food and Drug Administration (FDA) on key aspects of an Accelerated Approval pathway for its AMT-130 treatment, a potential therapy for Huntington’s disease.&nbsp;This agreement means data from the ongoing Phase I/II studies, compared to an external control, could serve as the primary basis for a biologics license application (BLA) submission without requiring an additional pre-submission study.uniQure’s AMT-130 previously received a regenerative medicine advanced therapy (RMAT) designation from the FDA in May, underscoring its potential to address unmet medical needs in Huntington’s disease.&nbsp;Analysts have viewed this development as a major milestone.Cantor Fitzgerald analyst Kristen Kluska raised her price target for uniQure to $58 from $28 and maintained an ‘Overweight’ rating, noting that the FDA’s approval signals potential pharma interest given the clearer path toward market entry.Stifel also weighed in, describing the development as “a best-case scenario” and noting that uniQure can use external controls and data from ongoing studies.&nbsp;Stifel has a ‘Buy’ rating and predicts the FDA agreement will bolster confidence in uniQure’s pipeline, despite the low initial expectations for this accelerated pathway.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QURE_sentiment_and_message_volume_Dec_10_premarket_98c55fcc19.png" alt="QURE sentiment and message volume Dec 10 premarket.png" width="1318" height="324"><figcaption>QURE sentiment and message volume Dec 10 premarket as of 11:45 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish’, with QURE trending among the top 10 tickers late Tuesday morning.<stembedurl>https://stocktwits.com/nbkihy8/message/595867060</stembedurl><stembedurl>https://stocktwits.com/DaBeavzz65/message/578931944</stembedurl>uniQure’s stock has more than doubled in value this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Neurons in dementia, conceptual illustration - stock illustration

uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More Optimistic

uniQure’s AMT-130 previously received a regenerative medicine advanced therapy designation from the FDA in May.

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA PR...

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

QURE
uniQure N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QURE News

QURE uniQure N.V.